Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

April 7, 2008

Primary Completion Date

April 30, 2020

Study Completion Date

May 24, 2022

Conditions
Prostate Cancer
Interventions
DRUG

triptorelin

PROCEDURE

adjuvant therapy

RADIATION

3-dimensional conformal radiation therapy

Trial Locations (17)

14076

Centre Regional Francois Baclesse, Caen

31052

Institut Claudius Regaud, Toulouse

33075

Hopital Saint Andre, Bordeaux

33076

Institut Bergonie, Bordeaux

34298

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier

42270

Institut de Cancerologie de la Loire, Saint-Priest-en-Jarez

44805

Centre Regional Rene Gauducheau, Saint-Herblain

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

68024

Hopitaux Civils de Colmar, Colmar

69373

Centre Leon Berard, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75015

Hopital Europeen Georges Pompidou, Paris

76038

Centre Henri Becquerel, Rouen

82017

Clinique du Pont de Chaume, Montauban

86021

CHU Poitiers, Poitiers

94000

Centre Hospitalier Universitaire Henri Mondor, Créteil

F-94805

Institut Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

UNICANCER

OTHER

NCT00667069 - Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | Biotech Hunter | Biotech Hunter